Reck et al. [80] demonstrated that pembrolizumab is associated with increased PFS and OS as well as a reduction in the incidence of treatment-related adverse events in advanced NSCLC patients who have not received prior treatment or have a PD-L1+ tumor rate of > 50%. Here, CD274 is linked to non-small cell lung carcinoma.